Albert Einstein College of Medicine

Massachusetts Institute of Technology

Ifo-Regina Elena Cancer Institute

Cornell University

The State University of New York

King's College London

Montefiore Medical Center

John S Condeelis

Frank B Gertler

David Entenberg

Maja H Oktay

Douglas A Lauffenburger

Madeleine J Oudin

Sonia E Voiculescu

Jason Neil

Forest White

Sumanta Goswami

James Castracane

Paola Nisticò

Thomas Rohan

Allison S Harney

Christopher Boyce Burge

Joan Jones

Tony Tsz-Cheong Ng

Joan G Jones

Wu Albert Cheng

Irina M Shapiro

Antonia Patsialou

Shannon K Hughes-Alford

Lauren Sfakis

Logan Butt

Shannon K Hughes

Gregory Weitsman

Paola Nistico

Methods of reducing chemotherapy-induced metastasis, or chemotherapy-induced cancer cell dissemination, for patients subject to chemotherapy using Tie-2 inhibitors. Methods of reducing chemotherapy-induced metastasis, or chemotherapy-induced cancer cell dissemination, for patients subject to chemotherapy using inhibitors of Mena expression and/or function are also provided.

Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism

A combination of markers (TMEM, MenaCalc, and MenalNV) for hematogenous metastatic cancer and their use for diagnosis, prognosis and predictive performance are disclosed.

Combined markers for metastatic cancer and uses thereof

Methods and apparatus are provided for high resolution intravital imaging and for chronic optical imaging of tissues such as lung.

High resolution intravital imaging and uses thereof

Disclosed are kits and methods for detecting the presence of tumor sites that are active in tumor cell dissemination and uses thereof for determining the risk of tumor cells undergoing hematogenous metastasis, for assessing the prognosis of a subject undergoing treatment for a localized tumor, for determining a course of treatment for a localized tumor, and for identifying agents to treat or prevent hematogenous metastasis.

TMEM active test and uses thereof in diagnosis, prognosis and treatment of tumors

Method for treating neoadjuvant chemotherapy-induced metastasis

Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin:total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided.

Phosphocofilin: cofilin co-localization intensity as a predictor of metastatic recurrence

Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on Mena.

Methods involving Menain screening for inhibitors of cancer invasion and metastasis

A microfluidic intravital window includes an intravital imaging window adapted for implantation adjacent target tissue of a live animal, and a microfluidic fluid source and delivery system physically integrated into the window for controlled delivery of fluids to target tissue via the window. The microfluidic fluid source and delivery system is self-contained and completely located within the intravital imaging window, and includes at least one preloaded fluid reservoir, at least one fluid port in fluidic communication with both the at least one preloaded fluid reservoir and the target tissue, and at least one light activated fluid flow control device situated between the at least one preloaded fluid reservoir and at least one fluid port, to facilitate simultaneous in vivo viewing and remotely controlled fluid delivery to the target tissue.

Microfluidic intravital window

[object Object]

Methods and products are provided for determining if a subject having a tumor is (i) at risk of metastasis of the tumor, or (ii) at risk of recurrence of the tumor after treatment of the tumor. Methods of treatment of cancer, tumors and metastasis are also provided.

Human invasion signature for prognosis of metastatic risk

The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and/or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control.

Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer

Methods and kits for diagnosis, prognosis and treatment of metastatic tumors are provided where the metastatic tumor is characterized by changes in expression of +++, ++ and/or 11a variants of Mena.

Metastasis specific splice variants of Mena and uses thereof in diagnosis, prognosis and treatment of tumors

Disclosed are methods for determining the risk of tumor cells undergoing metastasis, for assessing the prognosis of a subject undergoing treatment for a localized tumor, and for determining a course of treatment for a localized tumor comprising detecting the presence of an endothelial cell, a macrophage, and an invasive tumor cell in direct apposition in a tumor sample from a subject.

Tumor microenvironment of metastasis (TMEM) and uses thereof in diagnosis, prognosis and treatment of tumors

Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors

Growing community of inventors

City Island, NY, United States of America

John S Condeelis